Communiqués OraSure Technologies, Inc.

Actions

OSUR

US68554V1089

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX 19:22:42 18/09/2026			Varia. 5j.	Varia. 1 janv.
3,485 ^USD	-0,14 %		+7,23 %	+44,01 %

03:35	Islet Management engage des discussions avec OraSure Technologies	CI
06/08	Transcript : OraSure Technologies, Inc., Q2 2026 Earnings Call, Aug 05, 2026

Communiqués

05/08	OraSure: Q2 Earnings Snapshot	AQ
05/08	OraSure Announces Second Quarter 2026 Financial Results	GL
22/07	OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th	GL
21/07	OraSure Receives Emergency Use Authorization for Second Generation Ebola Test	GL
11/06	OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections	GL
11/06	OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections	AQ
06/05	OraSure: Q1 Earnings Snapshot	AQ
06/05	OraSure Announces First Quarter 2026 Financial Results	GL
22/04	OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th	GL
17/04	OraSure Technologies Appoints John D. Bertrand to its Board of Directors	GL
30/03	OraSure Technologies : 525.2 KB	PU
17/03	OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital	GL
17/03	Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance	BU
25/02	OraSure: Q4 Earnings Snapshot	AQ
25/02	OraSure Announces Fourth Quarter 2025 Financial Results	GL
10/02	OraSure to Launch OraQuick™ HIV Self-Test in Canada	GL
09/02	OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th	GL
15/01	OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital	GL
15/01	Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors	BU
05/01	OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review	GL
05/01	OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review	AQ
17/12	OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates	GL
17/12	Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors	BU
17/11	OraSure to Participate in Upcoming Investor Conference	GL
05/11	OraSure: Q3 Earnings Snapshot	AQ